Curated News
By: NewsRamp Editorial Staff
July 13, 2026

NanoViricides Gets Ethics Nod for Ebola Oral Gummies Trial in DRC

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • NanoViricides' NV-387 oral gummies for Ebola gain ethics approval, offering first oral treatment advantage over infusions.
  • NV-387 targets host-cell features used by viruses, enabling broad-spectrum antiviral activity against multiple viruses including Ebola.
  • Orally administered Ebola treatment could improve access and outcomes in resource-limited outbreak settings, saving lives.
  • NV-387 is the only oral Ebola treatment under clinical evaluation, with potential to treat Bundibugyo ebolavirus without approved therapies.

Impact - Why it Matters

This news matters because the current Bundibugyo ebolavirus outbreak in the DRC lacks approved therapies or vaccines. NanoViricides' NV-387 oral gummies, if successful, could provide a convenient, orally administered treatment that is easier to distribute in resource-limited settings compared to traditional infusions. This could significantly improve outbreak response and save lives, especially in remote areas. Additionally, the broad-spectrum antiviral platform may offer a rapid response to future viral threats.

Summary

NanoViricides, Inc. (NYSE American: NNVC) has announced a significant step forward in the fight against Ebola, receiving National Ethics Committee approval in the Democratic Republic of the Congo (DRC) for a Phase II clinical trial of its NV-387 oral gummies. This treatment targets the current Bundibugyo ebolavirus outbreak. The company is preparing to submit a Clinical Trial Application to the DRC regulatory agency, ACOREP, and crucially, the NV-387 drug product is already in the country for an upcoming Phase II Mpox trial, enabling rapid trial initiation if regulatory approval is received. This positions NV-387 as the only orally administered Ebola treatment currently under consideration for clinical evaluation, offering potential advantages over infusion-based therapies in resource-limited outbreak settings.

NanoViricides believes its broad-spectrum antiviral platform, designed to target host-cell features used by viruses, could provide a treatment option for Bundibugyo and other ebolaviruses that currently have no approved therapies or vaccines. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral drug being developed for various viral infections, including RSV, COVID, Long COVID, Influenza, MPOX/Smallpox, and Measles. The company's advanced drug candidate, NV-HHV-1, is for the treatment of Shingles. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials.

For more details, the full press release is available at https://ibn.fm/MuxOe. NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy, based on the TheraCour® nanomedicine technology. The company holds exclusive licenses for several drugs targeting a wide range of viral diseases, including HIV, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses. The company's newsroom is accessible at https://ibn.fm/NNVC for the latest updates.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Gets Ethics Nod for Ebola Oral Gummies Trial in DRC

blockchain registration record for this content.